Citigroup Boosts Health Catalyst (NASDAQ:HCAT) Price Target to $10.50

Health Catalyst (NASDAQ:HCAT) had its target price hoisted by Citigroup from $9.00 to $10.50 in a research note published on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other analysts have also issued reports about the stock. Piper Sandler reduced their price objective on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 26th. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a research note on Friday, October 4th. Royal Bank of Canada increased their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research report on Thursday, November 7th. Evercore ISI increased their price target on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $11.71.

Health Catalyst Stock Performance

NASDAQ HCAT opened at $8.66 on Wednesday. The company has a 50-day simple moving average of $8.13 and a two-hundred day simple moving average of $7.20. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst has a 12-month low of $5.42 and a 12-month high of $11.41. The firm has a market cap of $526.96 million, a price-to-earnings ratio of -6.41 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The firm had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. Health Catalyst’s revenue was up 3.5% on a year-over-year basis. During the same period last year, the business earned ($0.22) EPS. On average, equities analysts forecast that Health Catalyst will post -0.35 EPS for the current year.

Insider Transactions at Health Catalyst

In other news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $7.70, for a total value of $40,109.30. Following the transaction, the chief operating officer now owns 129,690 shares of the company’s stock, valued at $998,613. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $7.70, for a total transaction of $40,109.30. Following the completion of the transaction, the chief operating officer now directly owns 129,690 shares of the company’s stock, valued at approximately $998,613. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the sale, the insider now directly owns 255,881 shares in the company, valued at approximately $1,847,460.82. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 34,068 shares of company stock valued at $257,555. Corporate insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

A number of large investors have recently modified their holdings of the business. Quest Partners LLC purchased a new stake in shares of Health Catalyst during the 3rd quarter valued at approximately $34,000. Nisa Investment Advisors LLC increased its holdings in Health Catalyst by 461.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after purchasing an additional 5,232 shares during the last quarter. Quarry LP boosted its holdings in Health Catalyst by 59.4% during the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after acquiring an additional 2,610 shares during the period. nVerses Capital LLC acquired a new position in shares of Health Catalyst in the third quarter valued at approximately $59,000. Finally, Perfromance Wealth Partners LLC purchased a new position in Health Catalyst in the second quarter valued at $64,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.